Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.

Journal of virology - 1 Sept 2007

Klei Herbert E, Kish Kevin, Lin Pin-Fang M, Guo Qi, Friborg Jacques, Rose Ronald E, Zhang Yaqun, Goldfarb Valentina, Langley David R, Wittekind Michael, Sheriff Steven

Abstract excerpt

Atazanavir, which is marketed as REYATAZ, is the first human immunodeficiency virus type 1 (HIV-1) protease inhibitor approved for once-daily administration. As previously reported, atazanavir offers improved inhibitory profiles against several common variants of HIV-1 protease over those of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crystallography, X-Ray
Share to Drug Resistance, Viral
Share to HIV Protease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease Inhibitors

Share to Models, Molecular

Share to Oligopeptides

Share to Protein Structure, Tertiary

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 17537865
DOI: 10.1128/JVI.02503-05
PMCID: PMC1951392

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17537865-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.PMID 17537865Read ↗

HIV Protease: Historical Perspective and Current ResearchSemantic proximity Read ↗

Comprehending the Structure, Dynamics, and Mechanism of Action of Drug-Resistant HIV ProteaseSemantic proximity Read ↗

A small molecule, ACAi-028, with anti-HIV-1 activity targets a novel hydrophobic pocket on HIV-1 capsidSemantic proximity Read ↗

How Mutations Can Resist Drug Binding yet Keep HIV-1 Protease Functional.Semantic proximity Read ↗

Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease.Semantic proximity Read ↗

Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse TranscriptaseSemantic proximity Read ↗

Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.Semantic proximity Read ↗

Non-active site mutations in the HIV protease: Diminished drug binding affinity is achieved through modulating the hydrophobic sliding mechanism.Semantic proximity Read ↗

Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.Semantic proximity Read ↗

Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.Semantic proximity Read ↗

HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics.Semantic proximity Read ↗

Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.